Understanding Placebo Responses in Alzheimer's Disease Clinical Trials from the Literature Meta-Data and CAMD Database
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The placebo response and the underlying disease progression is difficult to differentiate in longitudinal Alzheimer's disease (AD) studies, yet it is crucial to understand for designing clinical trials and interpreting results. OBJECTIVES: The placebo response in ADAS-cog11 from various studies was evaluated against model predictions derived from historical placebo data to demonstrate potential interpretation of study results using a prior understanding of expected disease progression. METHODS: The placebo response component from a previously published disease progression model was used to estimate the longitudinal placebo response, and the disease progression in the placebo group in various case studies were evaluated. In addition, placebo data from the Coalition Against Major Diseases (CAMD) database in mild to moderate AD patients is described. RESULTS: The case studies demonstrated potential different results in disease progression in a placebo group, and the impact on understanding the magnitude of drug effect. Baseline cognitive function is an important covariate of disease progression, therefore, it is important to evaluate the baseline severity and predict disease progression accordingly when comparing trial results. Furthermore, study duration, sample size, and study design may affect the placebo response, all of which have the potential to confound understanding of study results. CONCLUSION: The recent failures in Phase III AD studies are not likely due to insufficient cognitive decline in the control groups. A meta-analytic approach using all available data provides a robust understanding of placebo effect, disease progression, and potential interpretation of treatment effects, and offers a useful tool to aid in both trial design and interpretation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies in AD suggest that study durations of 18 months are required to observe a decline in placebo groups52”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [52]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52109.x · Cited by 241 · cited 2×
“Data used in this analysis were obtained either from the public Study 1 data are obtained from two clinical studies [5, 6] conducted in different time, different sites, and for different drugs, but both studies were 52-week Phase II studies.”
Holford, N. H. G., & Peace, K. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11466 · Cited by 91 · cited 5×
“Thediagnosticcriteriafordementiaand probableADweresameasCaseStudy1above probableADweresameasCaseStudy1above. froma78-week,multi-center,double-blind,4dose cohorts,ascendingdosestudy, Alzheimer’s Disease Trials Drug B) at different times.”
InfluentialRogers, J. A., Polhamus, D. G., Gillespie, W. R., Ito, K., Romero, K., Qiu, R., Stephenson, D. T., Gastonguay, M. R., & Corrigan, B. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9263-3 · Cited by 81 · cited 1×
“Baseline severity is a very important factor when recently, Rogers et al. [17] conducted a meta-analysis combining patient-level and summary-level data and developed disease progression model to describe patients.”
Self-citationSamtani, M. N., Farnum, M., Lobanov, V., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V., & Initiative, A. T. A. D. N. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405497 · Cited by 80
Romero, K., de Mars, M., Frank, D., Anthony, M., Neville, J., Kirby, L., Smith, K., & Woosley, R. L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.165 · Cited by 55
Self-citationRomero, K., Corrigan, B., Neville, J., Kopko, S., & Cantillon, M. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.51 · Cited by 15
Self-citationMonsch, A. U., Spiegel, R., Berres, M., & Miserez, A. R. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2255 · Cited by 1
Cited by
Orr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 334
“Prior studies in AD suggest that study durations of 18 months are required to observe a decline in placebo groups 52 , providing a framework for trial lengths to assess efficacy.”
Beisteiner, R., Matt, E., Fan, C., Baldysiak, H., Schönfeld, M., Philippi Novak, T., Amini, A., Aslan, T., Reinecke, R., Lehrner, J., et al. (2020) · Advanced Science · doi:10.1002/advs.201902583 · Cited by 269
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., Priller, J., Rapp, M. A., & Rieckmann, N. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.007 · Cited by 212
“AD Donezepil 18 (0-35) 19 (6-33) 12-54 weeks AD Galantamine 25 (8-49) 16 (9-26) 12-28 weeks AD Ginkgo 9 (2-28) 8 (3-23) 12-26 weeks AD Memantine 17 (3-34) 17 (2-33) 24 weeks-22 months AD Rivastigmine 24 (13-33) 13 (6-16) 12-24 weeks MCI drug 40 (32-43) 27 (17-31) 24 weeks -48 months AD exercise 5 (0-20) 17 (2-25) 6-24…”
Remington, R., Bechtel, C., Larsen, D., Samar, A., Doshanjh, L., Fishman, P., Luo, Y., Smyers, K., Page, R., Morrell, C., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142499 · Cited by 134
Implementation of Quantitative and Systems Pharmacology in Large Pharma
Visser, S. A. G., de Alwis, D. P., Kerbusch, T., Stone, J. A., & Allerheiligen, S. R. B. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.40 · Cited by 91
Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00336-2 · Cited by 79
“Cognitive functions of AD patients were improved by 29% in the CMA group, whereas they were improved only by 14% in the placebo group after 84 days, consistent with a placebo effect that is seen in other AD clinical trials [50, 65, 66].”
BackgroundResultRemington, R., Bechtel, C., Larsen, D., Samar, A., Page, R., Morrell, C., & Shea, T. B. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-151098 · Cited by 77
“2) [8, 17–34].”
Disease Progression Modeling: Key Concepts and Recent Developments
Cook, S. F., & Bies, R. R. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0066-x · Cited by 97
Popescu, T., Pernet, C. R., & Beisteiner, R. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12121 · Cited by 78
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
Voss, T., Li, J., Cummings, J., Farlow, M., Assaid, C., Froman, S., Leibensperger, H., Snow‐Adami, L., McMahon, K. B., Egan, M., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.004 · Cited by 56
“Placebo responses occur in AD cognition studies, and consequently, studies need to be sufficiently long—at least 12 weeks in early phase studies— to be sure that the placebo response is exhausted [21].”
BackgroundMatt, E., Dörl, G., & Beisteiner, R. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12245 · Cited by 55
“16 Additionally, our previous neuropsychological and functional data showed that treatment response was confined to stimulated areas.”
Non-drug Therapies for Alzheimer’s Disease: A Review
Li, X., Ji, M., Zhang, H., Liu, Z., Chai, Y., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00416-x · Cited by 59
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Zach, N., Ennist, D. L., Taylor, A. A., Alon, H., Sherman, A., Kueffner, R., Walker, J., Sinani, E., Katsovskiy, I., Cudkowicz, M., et al. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0336-z · Cited by 46
“org/programs/camd/simulation-tool/) [12].”
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.03.001 · Cited by 46
“These results are consistent with the results of the disease progression models of Ito and colleagues [6,7], although they did not report individual-level analyses apart from ADNI.”
Dörl, G., Matt, E., & Beisteiner, R. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00362-8 · Cited by 40
“However, as already discussed, the complex functional and behavioral responses shown here and elsewhere [7] argue against a global placebo response [25].”
Development of a unified clinical trial database for Alzheimer's disease
Neville, J., Kopko, S., Broadbent, S., Avilés, E., Stafford, R., Solinsky, C. M., Bain, L. J., Cisneroz, M., Romero, K., Stephenson, D., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.005 · Cited by 37
“The placebo effects quantitative description allows researchers to envision scenarios regarding magnitude, duration, and variability of the placebo response, according to the selected entry criteria for the simulated trial [17].”
BackgroundInfluentialSelf-citationA geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 38
Czerniak, E., Oberlander, T. F., Weimer, K., Kossowsky, J., & Enck, P. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00169 · Cited by 40
“The first example for a PbP without being classified as such can be seen in patients with Alzheimer’s disease (37, 38), where caregivers often report clinical symptoms on behalf of the patient and thus may influence treatment outcomes.”
BackgroundRuthirakuhan, M. T., Herrmann, N., Gallagher, D., Andreazza, A. C., Kiss, A., Verhoeff, N. P. L. G., Black, S. E., & Lanctôt, K. L. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100385 · Cited by 31
“Finally, a strong placebo effect can complicate the interpretation of placebo-controlled trials of agitation in AD [57].”
BackgroundSinke, C., Forkmann, K., Schmidt, K., Wiech, K., & Bingel, U. (2016) · Cortex · doi:10.1016/j.cortex.2016.02.008 · Cited by 28
Hannestad, J., Duclos, T., Chao, W., Koborsi, K., Klutzaritz, V., Beck, B., Patel, A. K., Scott, J., Thein, S. G., Cummings, J. L., et al. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210011 · Cited by 24
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
“…change from baseline score at 18 months in the placebo arm could be different by 2 points (i.e., higher change from baseline due to faster progression in the more impaired population with 18-point MMSE score), 67 which is similar to the maximum symptomatic effect obtained with 5 mg of donepezil.”
BackgroundResultSelf-citationMullin, A. P., Corey, D., Turner, E. C., Liwski, R., Olson, D., Burton, J. K., Sivakumaran, S., Hudson, L. D., Romero, K., Stephenson, D. T., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12845 · Cited by 21
Self-citationConrado, D. J., Larkindale, J., Berg, A. K., Hill, M., Burton, J. K., Abrams, K. R., Abresch, R. T., Bronson, A., Chapman, D. S., Crowther, M. J., et al. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09642-7 · Cited by 21
Self-citationThe placebo phenomenon and the underlying mechanisms
Theodosis‐Nobelos, P., Filotheidou, A., & Triantis, C. (2020) · HORMONES · doi:10.1007/s42000-020-00243-5 · Cited by 23
Zhang, N., Zheng, X., Liu, H., Zheng, Q., & Li, L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00630-5 · Cited by 18
The Predictive Safety Testing Consortium and the Coalition Against Major Diseases
Stephenson, D. T., & Sauer, J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4440 · Cited by 15
Self-citationFarah, B. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00133 · Cited by 18
“However, due to the low level of reported ketosis and the inherent variability in the disease state and cognitive testing, the results of a single patient must be viewed in the context of a case study, and further studies are warranted.”
BackgroundChen, Y., Ni, X., Fleisher, A., Zhou, W., Aisen, P. S. S., & Mohs, R. C. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.12.002 · Cited by 14
“When changes from baseline are modeled, baselineMini–Mental Status Examination and/or baseline Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) are important covariates for rate of progression [3].”
BackgroundMethodStrategies to minimize placebo effects in research investigations
Rodrigues, F. B., & Ferreira, J. J. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.04.002 · Cited by 13
Mimenza-Alvarado, A. J., Aguilar-Navarro, S. G., Martínez-Carrillo, F. M., Ríos-Ponce, A. E., & Villafuerte, G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.729872 · Cited by 11
Du, L., Zhao, Y., Zhang, J., Shang, M., Zhang, J., & Han, J. (2023) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2023.3325380 · Cited by 13
“In addition, the baseline status, i.e., the intercept, is also correlated to the disease progression [30], [34].”
BackgroundZhang, N., Lv, Y., Li, H., Chen, J., Li, Y., Yin, F., Li, L., & Zheng, Q. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-02620-x · Cited by 12
“(5), the model structure is analogous to Ito 2013 [8]).”
BackgroundChen, X., Walton, K. L., Brodaty, H., & Chalton, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231222 · Cited by 13
“Current trial lengths varied between 12 weeks to 2 years (see Table 2 for details); majority fell below the suggestion of at least 18-months to detect cognitive decline in placebo groups, based on the estimated rate of disease progression in mild to moderate AD [186].”
Yuluğ, B., Altay, Ö., Li, X., Hanoğlu, L., Çankaya, Ş., Velioğlu, H. A., Lam, S., Yang, H., Coşkun, E., İdil, E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae478 · Cited by 11
Sato, K., Niimi, Y., Ihara, R., Suzuki, K., Iwata, A., & Iwatsubo, T. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2023.1320329 · Cited by 9
Placebo effect in subjects with cognitive impairment
Ito, K., & Romero, K. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.032 · Cited by 9
Self-citationCombined Metabolic Activators Improves Cognitive Functions in Alzheimer's DiseasePreprint
Yuluğ, B., Altay, Ö., Li, X., Hanoğlu, L., Çankaya, Ş., Lam, S. C. C., Yang, H., Coşkun, E., İdil, E., Nogaylar, R., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924201 · Cited by 8
Watanabe, M., Nakamura, Y., Yoshiyama, Y., Kagimura, T., Kawaguchi, H., Matsuzawa, H., Tachibana, Y., Nishimura, K., Kubota, N., Kobayashi, M., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.07.004 · Cited by 6
“Furthermore, somewhat transient improvement of ADAS-cog scores were observed at around week 8 in these two studies (EIS-161 and JPN-5), which appears to be due to placebo effect as suggested in previous reports [7,8].”
ResultGeerts, H., & Spiros, Ä. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200688 · Cited by 8
“Based on (CoalitionAgainstMajorDiseases),arobust predictivemodelwasdeveloped[47]highlightingthe largevariabilityofplaceboresponses.”
Meer, N., & Fischer, T. W. (2024) · Journal of Nutrition and Metabolism · doi:10.1155/2024/9672969 · Cited by 7
“A placebo efect cannot be ruled out in dementia studies [82], especially as the blinding of subjects was not always clearly stated in the selected studies or was generally absent in open-label designs.”
BackgroundThe Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making
Starling, S., Kehoe, L. S., Burnett, B. K., Green, P., Venkatakrishnan, K., & Madabushi, R. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3467 · Cited by 7
Kim, A.-L., Lee, W. K., Kwon, S., Han, I. B., & Choi, B. H. (2026) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-025-00782-1 · Cited by 6
Quantifying placebo and trial participation effects on cognitive outcome measures in aging dogs
Simon, K. E., Russell, K. J., Mondino, A., Yang, C.-C., Case, B. C., Anderson, Z., Whitley, C., Griffith, E. H., Gruen, M. E., & Olby, N. J. (2025) · GeroScience · doi:10.1007/s11357-025-01822-3 · Cited by 5
“Dogs from both studies were selected using the same inclusion criteria given baseline cognitive function is imperative in evaluating the placebo effect in dementia patients [14].”
InfluentialMatthiesen, S. T., Rosenkjær, S., Pontén, M., Jensen, K. B., Gottrup, H., & Vase, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210108 · Cited by 3
“Therefore, it is important to investigate the contribution of these non-specific [16].”
Khan, A., Zubair, S., & Khan, S. (2021) · ADCAIJ ADVANCES IN DISTRIBUTED COMPUTING AND ARTIFICIAL INTELLIGENCE JOURNAL · doi:10.14201/adcaij2021102183196 · Cited by 5
Sequential parallel comparison design with two coprimary endpoints
Homma, G., & Daimon, T. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1987 · Cited by 2
“At Stage 2, we considered two cases where H1 was true: (a) The treatment effects were equal across both stages, that is, (μ0,2,1, μ1,2,1, μ0,2,2, μ1,2,2) = (8, 6, 3, 2) (case A); and (b) the treatment effect at Stage 2 was larger than that at Stage 1, that is, (μ0,2,1, μ1,2,1, μ0,2,2, μ1,2,2) = (10, 6, 5, 2) (case B).”
BackgroundEmerging Technologies and their Role in Regulatory Review
Colatsky, T. J. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch1 · Cited by 2
“…developed by the Critical Path Institute’s Coalition Against Major Diseases (CAMD) as an aid in the design and interpretation of clinical trials for drugs intended to treat mild to moderate Alzheimer’s disease (Rogers et al., 2012; Ito et al., 2013; Panegyres et al., 2014; Romero et al., 2015).”
BackgroundMethodA Contrastive Framework for Modeling Brain Heterogeneity in Precision Mental Health
Tong, X., Zhao, K., Lin, F. V., & Zhang, Y. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.07.022 · Cited by 1
Clinical Trial Simulation in Alzheimer’s Disease
Corrigan, B., Ito, K., Rogers, J. A., Polhamus, D. G., Stephenson, D. T., & Romero, K. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4939-1304-6_15 · Cited by 1
“without clear rationale for why a difference in placebo response would be observed, the clinical team concluded that the placebo response in the drug B study was not normal and needed more data to confirm the efficacy before taking further action (Ito et al. 2013).”
MethodResultSelf-citationXi, D., Zhang, M., Shang, M., Du, L., Han, J., & Initiative, A. D. N. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae728 · Cited by 1
“Ito et al. (2013) showed the significance of the baseline status in disease progression modeling, and Budgeon et al. (2017) demonstrated the effectiveness of the change rate of imaging QTs.”
Mental and behavioural disorders
Benedetti, F. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198843177.003.0012 · Cited by 1
Seeking a better landscape for therapy development in neuromuscular disorders
Larkindale, J., & Porter, J. D. (2017) · Muscle & Nerve · doi:10.1002/mus.25961
Murchison, C., Jaeger, B. C., Szychowski, J. M., Cutter, G., Roberson, E. D., & Kennedy, R. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215553
Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s Disease PatientsPreprint
Yuluğ, B., Altay, Ö., Li, X., Hanoğlu, L., Çankaya, Ş., Lam, S. C. C., Velioğlu, H. A., Yang, H., Coşkun, E., İdil, E., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1965067/v1
Zhang, N., Zheng, X., Liu, H., Zheng, Q., & Li, L. (2020) · Figshare · doi:10.6084/m9.figshare.12375539
Miao, L., Chen, H., Xiang, B., Yuan, Z., Luo, C., & Li, T. (2026) · Applied Soft Computing · doi:10.1016/j.asoc.2026.114716
Umar, M., Franjieh, K., White, A. L., Ward-Dones, E., Ismael, S., Roskey, R., Courseault, J., & Bix, G. J. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00761-5 · Cited by 2
“This nutraceutical formulation maintained the cognitive performance of 24 AD patients in a one-year open-label study [111] as opposed to the routine cognitive decline of participants receiving a placebo [112].”
Safety and tolerability of intranasal insulin in Parkinson’s disease
Johnson, J. C., Kashyap, B., Gustafson, S. K., O’Brien, M., Frey, W. H., Svitak, A. L., & Hanson, L. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1875165
Towards Improved P2X7R Cellular Models for Alzheimer’s Disease Drug Discovery
Agius, C. T. A., McKenzie, A. D. J., Woollett, K., Werry, E. L., & Kassiou, M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00089
Aging dogs exhibit heterogeneous cognitive decline trajectories: A longitudinal comparative model
Simon, K. E., Panek, W. K., Fefer, G., Mondino, A., Yang, C.-C., Baigi, S. R., Khan, M. Z., Case, B. C., Griffith, E. H., Gruen, M. E., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261487575
“90,91 In contrast, our fi ndings that sex and age at enrollment do not predict these clusters diverges from the trends commonly reported in human literature.”
Metadata
- Authors
- Ito, K., Corrigan, B., Romero, K., Anziano, R., Neville, J., Stephenson, D., & Lalonde, R.
- Affiliations
- Pfizer (United States) (US)
- Critical Path Institute (US)
- Corresponding author
- Ito, Kaori
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-08-20
- Volume
- 37
- Issue
- 1
- Pages
- 173-183
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1720001930
- Cited by
- 62
- References
- 9
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 4
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- placebo response, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Placebo Effect, Databases, Factual, Comprehension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.